Markets:

Overview

News

Currencies

International

Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

49.71 +0.97 (+1.99%)

Streaming Delayed Price Updated: 1:55 PM EDT, Aug 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show ↗

May 05, 2025

TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.

Via Benzinga

Why TG Therapeutics Stock Was Tumbling Today ↗

May 05, 2025

Via The Motley Fool

Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗

May 05, 2025

Via Benzinga

TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic ↗

May 05, 2025

The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million.

Via Stocktwits

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗

May 02, 2025

A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?

Via Chartmill

Why TG Therapeutics Stock Was Soaring This Week ↗

March 07, 2025

Via The Motley Fool

Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts ↗

January 15, 2025

Via Benzinga

TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate ↗

May 01, 2025

TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate

Via Chartmill

Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX). ↗

April 19, 2025

UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX).

Via Chartmill

Price Over Earnings Overview: TG Therapeutics ↗

April 14, 2025

Via Benzinga

Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗

April 05, 2025

Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX).

Via Chartmill

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche ↗

April 02, 2025

The companies both have drugs that treat relapsing forms of multiple sclerosis.

Via Investor's Business Daily

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher ↗

March 21, 2025

TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher.

Via Benzinga

TG Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

November 25, 2024

Via Benzinga

A Closer Look at TG Therapeutics's Options Market Dynamics ↗

November 21, 2024

Via Benzinga

How does TG THERAPEUTICS INC (NASDAQ:TGTX) stack up against Mark Minervini’s strategy? ↗

March 14, 2025

A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing?

Via Chartmill

TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued. ↗

March 10, 2025

Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? ↗

March 09, 2025

Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength.

Via Benzinga

Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week ↗

March 03, 2025

Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.

Via Stocktwits

Stocks Pivot Lower On Trade Fears, Manufacturing Data ↗

March 03, 2025

Despite earlier indicating a strong start to March, stocks are lower this afternoon amid trade war concerns.

Via Talk Markets

Topics Stocks / Equities World Trade

NASDAQ:TGTX stands out as a growth opportunity that won't break the bank. ↗

November 21, 2024

NASDAQ:TGTX is showing decent growth, but is still valued reasonably.

Via Chartmill

TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide ↗

March 03, 2025

The company has gained notoriety for its multiple sclerosis treatment.

Via Investor's Business Daily

Topics Earnings

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

What's Going On With TG Therapeutics Stock Tuesday? ↗

January 14, 2025

TG Therapeutics Inc (NASDAQ:TGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 12, 2024

Via Benzinga

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗

November 08, 2024

A Fed rate cut and a slew of big earnings reports filled out a busy week.

Via Investor's Business Daily

Topics Economy Government

TG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results ↗

November 04, 2024

The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.